BIOR logo

Biora Therapeutics (BIOR) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 June 2020

Indexes:

Not included

Description:

Biora Therapeutics focuses on developing innovative therapies for gastrointestinal diseases. The company combines biotechnology and advanced drug delivery systems to create effective treatments, aiming to improve patient outcomes and enhance the quality of life for those with digestive disorders.

Events Calendar

Earnings

Next earnings date:

Mar 26, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 18, 2024

Analyst ratings

Recent major analysts updates

18 Nov '24 HC Wainwright & Co.
Buy
13 Aug '24 HC Wainwright & Co.
Buy
22 July '24 HC Wainwright & Co.
Buy
16 May '24 HC Wainwright & Co.
Buy
02 Jan '24 HC Wainwright & Co.
Buy
02 Oct '23 HC Wainwright & Co.
Buy
15 Aug '23 HC Wainwright & Co.
Buy
27 July '23 HC Wainwright & Co.
Buy
16 May '23 HC Wainwright & Co.
Buy
10 Jan '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Biora Therapeutics Announces Funding Agreement with Existing Investors
Biora Therapeutics Announces Funding Agreement with Existing Investors
Biora Therapeutics Announces Funding Agreement with Existing Investors
BIOR
globenewswire.com12 August 2024

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. “We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestones, including anticipated partnering with large pharma,” said Eric d'Esparbes, Chief Financial Officer of Biora Therapeutics.

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
BIOR
globenewswire.com08 August 2024

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets.

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
BIOR
globenewswire.com11 June 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows: Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart Capsules Track:  Pioneering Devices to Increase the Reach of Peptide APIs Date & Time: Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern time Presenting Author: Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside representatives from Eli Lilly, Merck, and Novo Nordisk.

Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript
BIOR
seekingalpha.com15 May 2024

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Chuck Padala, Adi Mohanty, and Eric d'Esparbes. Participants include Joseph Pantginis, Rei Tan, and John Vandermosten. Welcome to Biora Therapeutics' First Quarter 2024 Financial Results Call.

Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript
BIOR
Seeking Alpha26 March 2024

Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript

Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript
BIOR
Seeking Alpha13 November 2023

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call.

Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q2 2023 Earnings Call Transcript
BIOR
Seeking Alpha14 August 2023

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings, and welcome to the Biora Therapeutics Second Quarter 2023 Earnings Call.

Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
BIOR
GlobeNewsWire15 July 2023

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company's management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time.

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
BIOR
GlobeNewsWire08 June 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.

Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript
BIOR
Seeking Alpha15 May 2023

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Kristy Grabowski - IR Aditya Mohanty - CEO & Director Eric d'Esparbes - EVP & CFO Conference Call Participants Yuan Zhi - B. Riley Securities Matthew Keller - H.C.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Biora Therapeutics?
  • What is the ticker symbol for Biora Therapeutics?
  • Does Biora Therapeutics pay dividends?
  • What sector is Biora Therapeutics in?
  • What industry is Biora Therapeutics in?
  • What country is Biora Therapeutics based in?
  • When did Biora Therapeutics go public?
  • Is Biora Therapeutics in the S&P 500?
  • Is Biora Therapeutics in the NASDAQ 100?
  • Is Biora Therapeutics in the Dow Jones?
  • When was Biora Therapeutics's last earnings report?
  • When does Biora Therapeutics report earnings?
  • Should I buy Biora Therapeutics stock now?

What is the primary business of Biora Therapeutics?

Biora Therapeutics focuses on developing innovative therapies for gastrointestinal diseases. The company combines biotechnology and advanced drug delivery systems to create effective treatments, aiming to improve patient outcomes and enhance the quality of life for those with digestive disorders.

What is the ticker symbol for Biora Therapeutics?

The ticker symbol for Biora Therapeutics is NASDAQ:BIOR

Does Biora Therapeutics pay dividends?

No, Biora Therapeutics does not pay dividends

What sector is Biora Therapeutics in?

Biora Therapeutics is in the Healthcare sector

What industry is Biora Therapeutics in?

Biora Therapeutics is in the Biotechnology industry

What country is Biora Therapeutics based in?

Biora Therapeutics is headquartered in United States

When did Biora Therapeutics go public?

Biora Therapeutics's initial public offering (IPO) was on 19 June 2020

Is Biora Therapeutics in the S&P 500?

No, Biora Therapeutics is not included in the S&P 500 index

Is Biora Therapeutics in the NASDAQ 100?

No, Biora Therapeutics is not included in the NASDAQ 100 index

Is Biora Therapeutics in the Dow Jones?

No, Biora Therapeutics is not included in the Dow Jones index

When was Biora Therapeutics's last earnings report?

Biora Therapeutics's most recent earnings report was on 14 November 2024

When does Biora Therapeutics report earnings?

The next expected earnings date for Biora Therapeutics is 26 March 2025

Should I buy Biora Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions